Algorithmic Model Predicts Immunotherapy Response

Researchers developed a tumor avatar system that accurately gauges how cancer patients respond to immunotherapy treatments.

Updated on Oct. 21, 2026 in Cancer

Algorithmic Model Predicts Immunotherapy Response

Live Poll

Do you believe new diagnostic technologies will make cancer treatments more effective for patients?

A new study published in Cell Reports Medicine demonstrates an algorithmic model capable of predicting cancer patient responses to immunotherapy with 93% accuracy. The method utilizes living tumor avatars to analyze how a patient's immune system interacts with targeted drugs.

Why it matters

Traditional precision medicine often fails to capture the complex crosstalk between tumors and the immune system, limiting the effectiveness of personalized treatment planning. This model provides a new way to measure these interactions to improve therapeutic outcomes.

The researchers utilized a training set of 124 patient tumor samples and an analysis panel consisting of 8 cytokines to measure immune responses. The study successfully predicted outcomes in 93% of 28 tested patient tumor samples.

The players

Elephas Biosciences

A Wisconsin-based biotechnology company focused on advancing cancer research through ex vivo tumor models.

The details

By keeping biopsy samples alive in a dish as tumor avatars, scientists can treat the samples with immunotherapies and observe the reaction. The model measures signaling molecules known as cytokines, focusing specifically on markers for T-cell recruitment, immune cell killing activity, and immune regulation.

Elephas Biosciences launched in 2020.
The company raised $41.5 million in series B funding in 2022.
The firm secured an additional $40 million in 2025.
The study was published in Cell Reports Medicine on October 15, 2026.

Cancer
Oct. 20
Merck and Moderna Prepare Melanoma Vaccine Filing
Biotech
Oct. 13
ArsenalBio and TScan Shifted Biotech Strategies
Cancer
Sept. 18
EGFR Mutation Linked to Higher Lung Cancer Risk

Health Landscape

This development follows a pattern of recent advances in precision oncology published by the Cell Reports Medicine platform to improve cancer treatment accuracy. It represents a significant step in overcoming the limitations of static genomic testing in favor of live tumor analysis.

This diagnostic approach could eventually allow oncologists to determine the most effective immunotherapy for a patient before beginning a treatment regimen. Patients may experience faster identification of beneficial drugs and avoid the complications associated with ineffective therapies.

The takeaway

Using live tumor avatars offers a more dynamic view of how cancer interacts with the immune system than standard lab tests. This technology provides a bridge toward more accurate, personalized oncology treatments for patients.